Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Shanghai Pharmaceuticals Holding Co: Clinical Trials & FDA Approval Profile

Shanghai Pharmaceuticals Holding Co (Global / Institutional) sponsors 18 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (8 recruiting now), 9 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)53 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Shanghai Pharmaceuticals Holding Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)18
Active Pipeline (Recruiting Now)9 (8)
Completed vs Stopped Early9 / 0 (0.0%)
Median Closed Actual Enrollment53 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Shanghai Pharmaceuticals Holding Co
Hospital Research SiteLocationShared Protocols
Fujian Cancer HospitalFuzhou, Fujian6
Peking Union Medical College HospitalBeijing, Beijing Municipality6
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Shanghai Pharmaceuticals Holding Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05686642Efficacy and Safety of LT3001 on Treating the Acute Ischemic StrokePhase IIRECRUITING
NCT06434597A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.Phase IIRECRUITING
NCT05872347Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.Phase IIRECRUITING
NCT05860465Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast CancerPhase II/IIIRECRUITING
NCT05744687Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast CancerPhase II/IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Shanghai Pharmaceuticals Holding Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI